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ABSTRACT
Objectives In January 2020, the UK moved to a 1+1 
schedule for the 13- valent pneumococcal conjugate 
vaccine (PCV13) with a single priming dose at 3- month 
and a 12- month booster. We modelled the impact on 
invasive pneumococcal disease (IPD) out to 2030/2031 
of reductions in PCV13 coverage and population mixing 
associated with restrictions on non- essential healthcare 
visits and social distancing measures introduced in 
2020/2021 to reduce SARS- CoV- 2 transmission.
Design Using an existing model of pneumococcal 
transmission in England and Wales, we simulated the 
impact of a 40% reduction in coverage and a 40% 
reduction in mixing between and within age groups 
during two lockdowns in spring 2020 and autumn/winter 
2020/2021. More and less extreme reductions in coverage 
and mixing were explored in a sensitivity analysis.
Main outcome measures Predicted annual numbers of 
IPD cases under different coverage and mixing reduction 
scenarios with uncertainty intervals (UIs) generated from 
minimum and maximum values of the model predictions 
using 500 parameter sets.
Results The model predicted that any increase in IPD 
cases resulting from a reduction in PCV13 coverage would 
be more than offset by a reduction in pneumococcal 
transmission due to social distancing measures and that 
overall reductions in IPD cases will persist for a few years 
after resumption of normal mixing. The net reduction in 
cumulative IPD cases over the five epidemiological years 
from July 2019 was predicted to be 13 494 (UI 12 211, 
14 676) all ages. Similar results were obtained in the 
sensitivity analysis.
Conclusion COVID- 19 lockdowns are predicted to have 
had a profound effect on pneumococcal transmission 
resulting in a reduction in pneumococcal carriage 
prevalence and IPD incidence for up to 5 years after the 
end of the lockdown period. Carriage studies will be 
informative in confirming the predicted impact of the 
lockdown measures after they have been lifted.
INTRODUCTION
Following the first identification of local 
transmission of SARS- CoV- 2 in England on 28 
February 2020,1 the UK government instituted 
a series of control measures to reduce spread 
of the virus. On 18 March, schools along with 
restaurants and places of entertainment and 
leisure were closed, and on 23 March, all non- 
essential travel was banned with members of 
the population only permitted to leave their 
home for exercise once a day, or in order 
to obtain food or medication.2 The public 
was advised to only use the National Health 
Service when essential,3 and many general 
practices replaced face- to- face consultations 
with an online service.4 This first national 
lockdown was eased in stages starting in May 
2020 with children returning to schools in 
September 2020.5 As COVID- 19 cases started 
Strengths and limitations of this study
 ► For this study, we used a previously published dy-
namic model of pneumococcal transmission that 
was fitted to past data on age- specific pneumo-
coccal carriage and invasive pneumococcal disease 
(IPD) and was able to reproduce the observed herd 
immunity effects of the pneumococcal conjugate 
vaccination programme in England and Wales. 
Short- term model predictions of the effect of the 
first lockdown were validated against IPD data in 
England and Wales to June 2020.
 ► Our conclusions were robust under the extreme sce-
nario of assuming only a 10% reduction in mixing 
as a result of the two lockdowns and suspension of 
all 13- valent pneumococcal conjugate vaccine vac-
cination during the lockdown periods with no subse-
quent catch- up vaccination.
 ► A limitation of our model is uncertainty over the fu-
ture behaviour of non- vaccine serotypes, although 
this is unlikely to affect the overall conclusions.
 ► The predicted effect of the reduction in social mixing 
on carriage of pneumococci could potentially reduce 
development of natural immunity as a result of car-
riage, but we were unable with the current model 
structure to investigate this.
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to increase again in September 2020, a variety of locally 
based measures were introduced in areas of increasing 
incidence in an attempt to reduce transmission. Despite 
these local measures, cases continued to increase and a 
second national lockdown came into force in November 
2020, which lasted for 6 months until May 2021.5
In the UK, paediatric vaccinations are given in general 
practice and there was initial concern that the measures 
taken to limit spread of SARS- CoV- 2 would result in many 
children’s vaccinations being postponed with a resulting 
increase in vaccine- preventable infections.6 Indeed, 
early coverage data for measles/mumps/rubella vaccine 
for the first 3 weeks of the first lockdown in London 
suggested a drop of over 40% compared with the same 
period in 2019.7 Of particular concern is the impact of a 
drop in coverage of the 13- valent pneumococcal conju-
gate vaccine (PCV13) for which the national 2+1 schedule 
(2, 4 and 12 months) was changed on 1 January 2020 to a 
1+1 schedule at 3 and 12 months.8 The rationale for the 
schedule change was that after a decade of high coverage 
with PCV13 much of the protection of young children 
against vaccine- type invasive pneumococcal disease (IPD) 
is through herd immunity generated by the 12- month 
booster dose and that dropping a priming dose would 
have little effect on this. The supporting evidence for the 
schedule change came from an immunogenicity study 
showing similar postbooster antibody responses to PCV13 
serotypes with a 2+1 and 1+1 schedule9 and a modelling 
study, which predicted little impact on IPD cases in chil-
dren or adults if protection against vaccine- type carriage 
was similar postbooster with the two schedules.10
Using our previously described pneumococcal trans-
mission model,10 we investigated the impact on IPD if 
PCV13 coverage was substantially reduced during the 
lockdown periods in the UK. The model also allowed 
us to investigate the likely longer- term impact on pneu-
mococcal transmission of social mixing restrictions put 
in place to limit the spread of the SARS- CoV- 2 virus in 
England and Wales.
MODEL AND ASSUMPTIONS
The same compartmental deterministic model and esti-
mated parameter values as described by Choi et al10 were 
used in this study. Briefly, the model simulates the trans-
mission dynamics of carried pneumococci between and 
within different age groups and predicts carriage changes 
by serotype grouping, either vaccine type (VT) or non- 
vaccine type (NVT), under different vaccination scenarios. 
Carriage changes are then translated into IPD cases using 
case- carrier ratios (CCRs) that describe the invasive poten-
tial of different carried serotypes. The model has a suscep-
tible–infected–susceptible (SIS) structure, as it is assumed 
that a carriage episode does not generate any serogroup- 
specific protection. The model has 26 parameters that 
describe the propensity for vaccine- induced replacement 
of VTs with NVTs in carriage, the CCRs in different age 
groups, and the effectiveness of PCV vaccination against 
carriage of different vaccine serotypes (see online supple-
mental appendix for summary of model description 
and parameter estimation). The maximum likelihood 
values of these parameters and their uncertainty inter-
vals (UIs) are estimated by fitting the model to IPD data 
up to the end of the epidemiological year from July 2015 
to June 2016.10 In implementing the effect of the 1+1 
schedule, the base case in the model described by Choi 
et al10 assumed that one priming dose at 3 months of age 
provides half the protection against VT carriage as two 
doses, while the effect of the 12- month booster remains 
unchanged. In the current analysis, the change to the 
1+1 PCV13 schedule was implemented to reflect the 
actual start date of January 2020, not the assumed date of 
September 2018 as in the original model.10
We assumed that, during the first 2- month lockdown 
period starting from 23 March 2020 and also during the 
second 6- month lockdown starting from 5 November 
2020, there was a 40% reduction in PCV13 coverage, as 
suggested by early declines in Measles, Mumps and Rubella 
(MMR) vaccine coverage in London during the first lock-
down.7 For the sensitivity analysis, we assumed two addi-
tional scenarios, one with no material decline in PCV13 
coverage (0% decline) and a second with cessation of all 
PCV13 vaccination during the lockdown periods (100% 
decline). The 0% scenario was chosen to reflect a situa-
tion in which there was a rapid catch- up of missed PCV13 
vaccinations after the first lockdown with no reduction 
during the second, while the 100% reduction scenario 
was explored as an extreme scenario. We pessimistically 
assumed there would be no subsequent catch- up vacci-
nation for children under the 40% and 100% reduction 
scenarios, as final coverage data for the affected birth 
cohorts will not be available until 2021/2022.
To implement the impact of reduced social mixing 
during each of the lockdown periods, we used the same 
mixing matrix as before10 based on the POLYMOD 
study11 and an additional contact survey among infants 
under 1 year12 but reduced the number of contacts 
between and within each age group by 40% as a baseline 
scenario and explored 10% and 74% reduction scenarios 
for the sensitivity analysis. The 74% reduction scenario 
was based on early data from a study of the social contacts 
of 1356 UK adults between 24 and 27 March13 compared 
with the historical rates documented in the POLYMOD 
study.11 However, this study13 could not assess the impact 
on contacts made by children, particularly those of 
preschool age who are the main drivers of pneumococcal 
transmission.10 As the social distancing measures in chil-
dren were less strict than adults, the estimated reduction 
in mixing would be lower in children and so we took 
the 74% scenario as the upper extreme scenario for the 
contact pattern reduction.
The results are shown as the median of the model 
outputs under the different scenarios. The UI for each 
scenario represents the minimum and maximum values 
generated with 500 model parameters sets obtained from 
Choi et al.10 The impact on IPD of the temporary changes 
3Choi YH, Miller E. BMJ Open 2021;11:e045380. doi:10.1136/bmjopen-2020-045380
Open access
in PCV13 coverage and social mixing is presented by VT, 
which includes PCV13 serotypes minus serotypes 1 and 3, 
and NVT; serotype 3 is included with the NVT group in 
the model on the grounds that it has shown an increase 
post- PCV13 similar to that seem for NVTs, while serotype 
1 is excluded from the model due to secular changes 
which are independent of vaccine usage.10
Patient and public involvement statement
Our study did not involve any direct participation by 
human subjects.
RESULTS
Figure 1 shows the predicted number of IPD cases 
in England and Wales by epidemiological year out to 
2030/2031 in under 5 year olds and in 65+ year olds by 
VT and NVT group with four different scenarios. The first 
scenario presented in figure 1A,B is without any change 
in PCV13 coverage and contact patterns; the increase in 
IPD cases out to 2030/2031 in 65+ year olds reflects the 
increasing mean age of individuals in this age group in 
the future together with the steep increase in IPD inci-
dence with increasing age in the elderly population. The 
remaining three scenarios in figure 1C–H assume a 40% 
reduction in PCV13 coverage with respectively a 10% (C 
and D), 40% (E and F) or 74% (G and H) reduction in 
contact rates during the two lockdowns. Even with only 
a 10% reduction in contact rates in figure 1C,D, the 
predicted impact of reduced social mixing outweighed 
any increase in IPD due to reduction in PCV13 coverage. 
The predicted beneficial effect of the lockdown on IPD 
cases was even more marked with higher reductions in 
social mixing (figure 1E–H). Under all the scenarios, the 
model predicted that the impact of the two lockdowns on 
IPD would persist for up to 5 years after their cessation.
The cumulative number of additional IPD cases 
predicted in England and Wales over the first 5 epidemi-
ological years starting from July 2019 is shown in table 1 
by age group and serotype grouping for a 40% reduction 
in contact rates and 40% reduction in PCV13 coverage 
during two lockdowns (base case scenario). Across all 
ages, the model predicted a net saving of 13 494 IPD cases 
(UI 12 211, 14 676) over this period compared with the 
predicted number of IPD cases without any lockdowns. 
The results over the first 5 years by age group and different 
scenarios for the reduction in coverage and social mixing 
are presented in online supplemental table S1. Without 
any reduction in contact rates under the worst case of 
no PCV13 vaccination during the two lockdown periods 
and no catch- up vaccination, the model predicted a 
Figure 1 Predicted annual number of IPD cases by VT and NVT and epidemiological year (July to June) from 2018/2019 to 
2030/2031 with a 40% reduction in 13- valent pneumococcal conjugate vaccine coverage during the two lockdown periods 
starting from 23 March 2020 for 2 months and from 5 November 2020 for 6 months obtained from the long- term simulation 
model. (A) Under 5 year olds and (B) 65+ year olds without any reduction in contact rates. (C) Under 5 year olds and (D) 65+ year 
olds with 10% reduction in contact rates. (E) Under 5 year olds and (F) 65+ year olds with 40% reduction in contact rates. (G) 
Under 5 year olds and (H) 65+ year olds with 74% reduction in contact rates. Results show median and minimum and maximum 
of the range of model outputs generated by 500 model parameter sets.10 IPD, invasive pneumococcal disease; NVT, non- 
vaccine type; VT, vaccine types.
4 Choi YH, Miller E. BMJ Open 2021;11:e045380. doi:10.1136/bmjopen-2020-045380
Open access 
cumulative additional 105 (UI 49, 197) VT IPD cases, of 
which 14 (UI 6, 26) were in children under 2 years of age 
over the first 5 epidemiological years since 2019/2020. 
The overall predicted increase in IPD cases was smaller 
(73 (UI 33, 130)) due to a concomitant reduction in 
replacement with NVT IPD cases (figure 2). While the 
predicted overall increase is small, the perturbation in 
VT IPD cases as a result of the temporary interruption of 
vaccination is predicted to persist out to 2030/2031.
Amin- Chowdbury et al14 reported that there were 2440 
IPD cases in England and Wales between February and 
June 2019 and 1137 IPD cases during the same period 
in 2020 showing a 53% reduction in overall IPD cases 
in England and Wales. The model predicted that there 
would be 2350 (UI 2129, 2531) IPD cases in the same 
period in 2019.
Table 2 shows the model predictions for the reduc-
tion in IPD cases in February to June 2020 with a 40% 
reduction in PCV13 coverage during the two lockdown 
periods and under various reduced mixing scenarios. 
The scenario with a 40% reduction in mixing pattern 
most closely matched the observed reduction in IPD 
during February to June 2020.14 Online supplemental 
table S2 shows the predicted number of IPD cases during 
February to June 2020 with different assumptions about 
reductions in PCV13 coverage and in social mixing. Only 
the scenarios with a 40% reduction in mixing produced 
the observed reductions seen in IPD incidence with little 
impact of varying the PCV13 coverage reductions.
DISCUSSION
In line with many other countries, the UK adopted a lock-
down strategy to minimise social contacts and thereby 
reduce the spread of the SARS- CoV- 2. The restriction 
on non- essential travel and General Practice (GP) visits 
raised concerns that vaccine coverage in children might 
be substantially reduced,6 echoing similar concerns 
raised at the global level.15 With the recent change to a 
1+1 PCV13 schedule in the UK, which is reliant on the 
booster dose to maintain herd immunity,9 10 a substantial 
reduction in PCV13 coverage could compromise control 
of IPD. Our modelling study suggests that any potential 
impact of the lockdown measures on PCV13 coverage and 
herd immunity will be more than offset by a reduction 
in pneumococcal transmission due to the reduction in 
population mixing such that a net reduction in IPD cases 
should occur. Our model also predicts that the net reduc-
tion in IPD cases will be sustained for up to 5 years after 
mixing has returned to normal levels in the population. 
This reduction in IPD would be the result of an overall 
reduction in pneumococcal carriage prevalence after the 
two lockdown periods, unlike the IPD reduction achieved 
with PCV. Carriage studies in England before and after 
the introduction of PCVs have shown little impact on 
overall carriage prevalence with the reduction in carriage 
of vaccine serotypes offset by an increase in non- vaccine 
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by PCVs is the consequence of the generally lower CCRs 
of the NVTs that replaced VTs in carriage.
IPD is a consequence, although rare, of carriage of 
Streptococcus pneumoniae in the nasopharynx. Acquisition 
of the pneumococcus is by person- to- person transmis-
sion and occurs via respiratory droplets with transmission 
enhanced in settings with close mixing such as day care 
centres and military camps.17 Visits to the GP for mild 
upper respiratory tract disease have also been shown to be 
a risk factor for pneumococcal acquisition.18 It is, there-
fore, to be expected that the measures taken to reduce 
spread of SARS- CoV- 2 would also reduce pneumococcal 
transmission. The impact on IPD in England and Wales 
of the first UK lockdown that lasted for 2 months from 23 
March 2020 was recently reported.14 Our model simula-
tions of the impact of the first lockdown were similar and 
consistent with an overall reduction of 40% in contact 
patterns during this period.
Whether a reduction in coverage caused by the lock-
downs would have a similar effect on other vaccine- 
preventable infections cannot be assessed with our model 
as it is specific to pneumococcal infection. However, the 
average number of weekly notifications of whooping 
cough and meningococcal septicaemia in England for 
1 year from 23 March 2020 showed a 91.3% and 74.7% 
reduction, respectively, compared with the weekly average 
for the same period in 2019.19 As with IPD, nasopharyn-
geal colonisation is a prerequisite for whooping cough 
and meningococcal disease. While the completeness of 
notifications by doctors may have suffered somewhat as 
a result of the COVID- 19 epidemic, the magnitude of 
the decline in these two other infections is consistent 
with a substantial reduction in new colonisation episodes 
following the lockdown and suggests that, at least in the 
short term, this has outweighed any potential increase 
due to a reduction in coverage of pertussis or meningo-
coccal vaccines.
Our model has limitations as previously described.10 
These include uncertainty over the future behaviour 
of non- vaccine serotypes and whether serotypes with 
different invasiveness potential will emerge, and also 
in the mixing patterns among the oldest age groups. 
However, given the magnitude of the predicted effect of 
the lockdowns, these uncertainties are unlikely to mate-
rially affect the results with respect to the effect of the 
lockdowns. It is also possible that the reduction in pneu-
mococcal carriage predicted to occur as a result of the 
Figure 2 Predicted median difference between the scenario without any change in 13- valent pneumococcal conjugate vaccine 
(PCV13) coverage and social mixing, and another scenario without any reduction in social mixing and no PCV13 vaccination 
during the two lockdowns in 2020/2021 in the annual number of IPD cases, by serotype grouping (VT, NVT and overall) in all 
ages in England and Wales. IPD, invasive pneumococcal disease; NVT, non- vaccine type; VT, vaccine types.
Table 2 Model outputs for the number of overall IPD cases 
between February and June 2020 and proportional reduction 
compared with the model predictions for the same period in 
2019 (2350 (UI 2129, 2531) IPD cases) in England and Wales 
according to different reduction levels in contact patterns 
with 40% 13- valent pneumococcal conjugate vaccine 
coverage reduction rate during the first two lockdown 
starting from 23 March for 2 months in the UK
Reduction 
in mixing 2020 Proportional reduction
0% 2374 (2146, 2554) −0.9% (−1.3%, −0.6%)
10% 1954 (1766, 2102) 16.9% (16.5%, 17.3%)
40% 1125 (1017, 1211) 52.1% (51.8%, 52.4%)
74% 677 (612, 728) 71.2% (71.1%, 71.3%)
Results show median and minimum and maximum of the range of 
model outputs generated by 500 model parameter sets.10
IPD, invasive pneumococcal disease.
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lockdowns may affect induction of natural immunity. 
Nasopharyngeal carriage can boost serotype- specific IgG 
antibody levels to the carried serotype and such naturally 
induced capsular antibodies have been shown to protect 
against carriage of that serotype.20 If natural immunity 
against carriage was reduced as a result of decreased 
pneumococcal transmission this could offset the reduc-
tion in IPD predicted to persist after relaxation of the 
lockdown. Our model has an SIS structure so does not 
include a natural immunity compartment, so we were 
unable to explore the potential effect of such perturba-
tions in carriage- induced immunity. We were also unable 
to incorporate the actual coverage reductions during the 
two lockdown periods as coverage data for completed 
1+1 PCV13 courses is only available when a birth cohort 
reaches 2 years of age. Our baseline coverage reduction 
scenario may, therefore, have been extreme with catch- up 
vaccination rapidly offsetting any reduction during the 
two lockdown periods. However, as shown by the sensi-
tivity analysis, the critical parameter in determining 
impact was reductions in mixing, with only a 10% reduc-
tion having a profound effect on IPD cases.
In conclusion, our pneumococcal model predicts that 
the effect of the COVID- 19 lockdowns on pneumococcal 
carriage rates will result in a reduction in IPD cases 
over a 5- year period, thus obscuring the predicted small 
increase in VT IPD due to the adoption of a 1+1 PCV13 
schedule.10 Pneumococcal carriage studies conducted 
over the next few years could help elucidate the impact 
of the social distancing measures and of the adoption of 
the 1+1 PCV13 schedule on the future incidence of VT 
and NVT IPD.
Contributors YHC and EM conceived of the presented idea. YHC and EM developed 
the theory and YHC performed the computations. YHC and EM verified the analytical 
methods. YHC and EM discussed the results and contributed to the final manuscript.
Funding EM is funded by the National Institute for Health Research Health 
Protection Research Unit in Immunisation at the London School of Hygiene and 
Tropical Medicine in partnership with Public Health England (Grant Reference 
NIHR200929).
Competing interests None declared.
Patient consent for publication Not applicable.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iD
Yoon Hong Choi http:// orcid. org/ 0000- 0001- 5561- 4366
REFERENCES
 1 Coronavinus: first Covid- 19 transmission within the UK confirmed 
| inews. Available: https:// inews. co. uk/ news/ uk/ coronavirus- first- 
covid- 19- transmission- uk- confirmed- 2004500 [Accessed 31 Jul 
2020].
 2 COVID- 19: guidance on social distancing and for vulnerable people 
- GOV.UK. Available: https://www. gov. uk/ government/ publications/ 
covid- 19- guidance- on- social- distancing- and- for- vulnerable- people 
[Accessed 31 Jul 2020].
 3 NHS. Staying at home and away from others (social distancing) - 
GOV.UK. Available: https://www. gov. uk/ government/ publications/ full- 
guidance- on- staying- at- home- and- away- from- others/ full- guidance- 
on- staying- at- home- and- away- from- others [Accessed 31 Jul 2020].
 4 How to get medical help from home - Coronavirus (COVID- 19) - 
NHS. Available: https://www. nhs. uk/ conditions/ coronavirus- covid- 
19/ staying- at- home- to- avoid- getting- coronavirus/ how- to- get- 
medical- help- from- home/ [Accessed 31 Jul 2020].
 5 Baker C, Kirk- Wade E, Brown J. Coronavirus: a history of English 
lockdown laws. Available: https:// commonslibrary. parliament. uk/ 
research- briefings/ cbp- 9068/ [Accessed 2 May 2021].
 6 Missed vaccinations could lead to other fatal outbreaks, doctors 
warn | Society | the guardian. Available: https://www. theguardian. 
com/ society/ 2020/ apr/ 26/ missed- vaccinations- could- lead- to- other- 
fatal- outbreaks- doctors- warn [Accessed 31 Jul 2020].
 7 McDonald HI, Tessier E, White JM, et al. Early impact of the 
coronavirus disease (COVID- 19) pandemic and physical distancing 
measures on routine childhood vaccinations in England, January to 
April 2020. Euro Surveill 2020;25:2000848.
 8 Changes to the infant pneumococcal conjugate vaccine schedule. 
Available: https:// assets. publishing. service. gov. uk/ government/ 
uploads/ system/ uploads/ attachment_ data/ file/ 854153/ Letter_ 
NHSEI_ PHE_ PCV13_ schedule_ change. pdf [Accessed 31 Jul 2020].
 9 Goldblatt D, Southern J, Andrews NJ, et al. Pneumococcal conjugate 
vaccine 13 delivered as one primary and one booster dose (1 + 1) 
compared with two primary doses and a booster (2 + 1) in UK 
infants: a multicentre, parallel group randomised controlled trial. 
Lancet Infect Dis 2018;18:171–9.
 10 Choi YH, Andrews N, Miller E. Estimated impact of revising the 
13- valent pneumococcal conjugate vaccine schedule from 2+1 
to 1+1 in England and Wales: a modelling study. PLoS Med 
2019;16:e1002845.
 11 Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns 
relevant to the spread of infectious diseases. PLoS Med 2008;5:e74.
 12 van Hoek AJ, Andrews N, Campbell H, et al. The social life of infants 
in the context of infectious disease transmission; social contacts and 
mixing patterns of the very young. PLoS One 2013;8:e76180–7.
 13 Jarvis CI, Van Zandvoort K, Gimma A, et al. Quantifying the impact of 
physical distance measures on the transmission of COVID- 19 in the 
UK. BMC Med 2020;18:124.
 14 Amin- Chowdhury Z, Aiano F, Mensah A, et al. Impact of the 
coronavirus disease 2019 (COVID- 19) pandemic on invasive 
pneumococcal disease and risk of pneumococcal coinfection 
with severe acute respiratory syndrome coronavirus 2 (SARS- 
CoV- 2): prospective national cohort study, England. Clin Infect Dis 
2021;72:e65–75.
 15 Hirabayashi K. The impact of COVID- 19 on routine vaccinations: 
reflections during world immunization week, 2020. Available: https://
www. unicef. org/ eap/ stories/ impact- covid- 19- routine- vaccinations 
[Accessed 31 Jul 2020].
 16 Southern J, Andrews N, Sandu P, et al. Pneumococcal carriage in 
children and their household contacts six years after introduction of 
the 13- valent pneumococcal conjugate vaccine in England. PLoS 
One 2018;13:e0195799.
 17 Donkor ES. Understanding the pneumococcus: transmission and 
evolution. Front Cell Infect Microbiol 2013;3:7.
 18 Sleeman KL, Daniels L, Gardiner M, et al. Acquisition of 
Streptococcus pneumoniae and nonspecific morbidity in infants and 
their families: a cohort study. Pediatr Infect Dis J 2005;24:121–7.
 19 Notifiable diseases: weekly reports for 2020 - GOV.UK. Available: 
https://www. gov. uk/ government/ publications/ notifiable- diseases- 
weekly- reports- for- 2020 [Accessed 3 May 2021].
 20 Goldblatt D, Hussain M, Andrews N, et al. Antibody responses to 
nasopharyngeal carriage of Streptococcus pneumoniae in adults: a 
longitudinal household study. J Infect Dis 2005;192:387–93.
